FOLFOXIRI Protocol

DRUG5 trials

Sponsors

Sixth Affiliated Hospital, Sun Yat-sen University, Centre Hospitalier Universitaire Dijon, Catharina Ziekenhuis Eindhoven, Kasr El Aini Hospital, Al-Azhar University

Conditions

Chemotherapy EffectColon Cancer Stage 4Metastatic Colorectal CancerNeoplasm MalignantNeuroendocrine CarcinomaRectal Cancer

Phase 2

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

RecruitingNCT04325425

Centre Hospitalier Universitaire DijonNeuroendocrine Carcinoma

Start: 2020-09-01End: 2029-09-30Target: 218Updated: 2025-09-30

Induction Chemotherapy for Locally Advanced Rectal Cancer

Not yet recruitingNCT04838496

Catharina Ziekenhuis EindhovenRectal Cancer

Start: 2021-06-01End: 2026-06-01Target: 128Updated: 2021-04-09

Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma

CompletedNCT05316818

Kasr El Aini HospitalMetastatic Colorectal Cancer

Start: 2018-01-16End: 2021-04-10Updated: 2022-04-07

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

RecruitingNCT06575127

Al-Azhar UniversityColon Cancer Stage 4, Neoplasm Malignant

Start: 2024-08-17End: 2026-09-01Target: 60Updated: 2024-08-28

Phase 3

Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Not yet recruitingNCT03975049

Sixth Affiliated Hospital, Sun Yat-sen UniversityChemotherapy Effect, Rectal Cancer

Start: 2019-08-31End: 2029-07-31Target: 933Updated: 2019-06-05

Related Papers

Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).

2022-09-068 citations

First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial

Therapeutic Advances in Medical Oncology2022-01-0111 citations

FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.

2021-05-1216 citations